Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Group 1 - The company has made significant progress in clinical trials, particularly with the Phase II MASH trial, which provided data at both 24 weeks and 48 weeks [2] - The 48-week data set reinforces expectations for the upcoming Phase III trial design for pemvidutide in MASH [2] - The company anticipates an exciting year ahead in 2026, indicating ongoing developments and potential advancements [2]